Nanomed advance may fight brain tumors long considered death sentences

Researchers at the Medical University of South Carolina’s Center for Biomedical Imaging have engineered a lipid nanocarrier capable of carrying a concentrated dose of the chemotherapy drug TMZ directly into the cells of aggressive glioblastoma brain tumors.

“We take advantage of the tumor’s natural environment as well as the cellular expression,” Ann-Marie Broome, PhD, director of molecular imaging and lead author of a research paper describing the work, told the online nanotech publication AZoNano.

Broome adds that many past treatments have likely failed “because you have to take into account the immune system, the local environment and the cells themselves—all three of these are important considerations.”

Read the AZoNano news report:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.